Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1213-1214

  Müller, Dafne ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Antibody fusion protein; IL 15; IL 15Ra; Targeting; Trans presentation

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 15;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL SURFACE; CLINICAL TRIAL (TOPIC); DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; METASTATIC MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION;

EID: 84886944255     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20824     Document Type: Article

References (10)

1. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x.
2. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33:35-41; PMID:22032984; http://dx.doi.org/10.1016/j.tips.2011.09.004.
3. Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 2010; 127:85-92; PMID:19818367; http://dx.doi.org/10.1016/j.imlet.2009.09.009.
4. Stoklasek TA, Schluns KS, Lefrançois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177:6072-80; PMID:17056533.
5. Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/ CD44high T cells and its antitumor action. J Immunol 2008; 180:2099-106; PMID:18250415.
6. Bessard A, Solé V, Bouchaud G, Quéméner A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in meta-static melanoma and colorectal cancer. Mol Cancer Ther 2009; 8:2736-45; PMID:19723883; http://dx.doi.org/10.1158/1535-7163.MCT-09-0275.
7. Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, et al. Densely granulated murine NK cells eradicate large solid tumors. Cancer Res 2012; 72:1964-74; PMID:22374983; http://dx.doi.org/10.1158/0008-5472.CAN-11-3208.
8. Epardaud M, Elpek KG, Rubinstein M P, Yonekura AR, Bellemare-Pelletier A, Bronson R, et al. Interleukin-15/ interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008; 68:2972-83; PMID:18413767; http://dx.doi.org/10.1158/0008-5472.CAN-08-0045.
9. Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007; 67:4940-8; PMID:17510424; http://dx.doi.org/10.1158/0008-5472.CAN-07-0283.
10. Kermer V, Baum V, Hornig N, Kontermann RE, Müller D. An antibody fusion protein for cancer immu-notherapy mimicking IL-15 trans-presentation at the tumor site. Mol Cancer Ther 2012; Epub ahead of press; PMID:22491823; http://dx.doi.org/10.1158/1535-7163.MCT-12-0019.